The Causal Associations between Adipokines and Alzheimer’s Disease: A Two-Sample Mendelian Randomization Study

Background: Observational studies have indicated the association of alteration of adipokines with Alzheimer’s disease (AD). However, it remains unclear whether the associations are causal. Objective: To determine the causal associations between adipokines and AD. Methods: A Mendelian randomization (MR) method was applied to investigate the causal relationships of adipokines, including adiponectin and resistin, with risk of AD. Genetic proxies from genome-wide association studies (GWAS) of adiponectin and resistin were selected as instrumental variables. GWAS summary statistics for AD were extracted as outcome. Results: In this study, we found evidence of the causal effects of adiponectin on AD (OR: 0.850, 95% CI: 0.731-0.990, p = 0.037). However, no relationship between resistin and AD (OR: 0.936, 95% CI: 0.851-1.029, p = 0.171) was detected. In the reverse causation analysis, null associations of AD were found for adiponectin and resistin (all p > 0.05). Conclusions: This study provides evidence of causality between adiponectin and risk of AD. However, no genetic susceptibility of resistin was discovered for AD.

[1]  Yifan Cheng,et al.  Causal association between adiponectin and the risk of Alzheimer's disease: A Mendelian randomization study , 2022, Frontiers in Neurology.

[2]  Ali I. Al-Gareeb,et al.  A Potential Link Between Visceral Obesity and Risk of Alzheimer’s Disease , 2022, Neurochemical Research.

[3]  I. Rainero,et al.  Decreased resistin plasmatic concentrations in patients with Alzheimer's disease: A case-control study , 2022, Heliyon.

[4]  F. Yin.  Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise , 2022, The FEBS journal.

[5]  M. Ikram,et al.  Adiponectin, Leptin, and Resistin and the Risk of Dementia , 2021, The journals of gerontology. Series A, Biological sciences and medical sciences.

[6]  F. Mulè,et al.  From obesity to Alzheimer's disease through insulin resistance. , 2021, Journal of diabetes and its complications.

[7]  N. Samant,et al.  Adiponectin: a potential target for obesity-associated Alzheimer’s disease , 2021, Metabolic Brain Disease.

[8]  Liang Shen,et al.  Associations Between Obesity and Alzheimer's Disease: Multiple Bioinformatic Analyses. , 2021, Journal of Alzheimer's disease : JAD.

[9]  C. Ochner,et al.  Alzheimer’s Disease, Inflammation, and the Role of Antioxidants , 2020, Journal of Alzheimer's disease reports.

[10]  Deeksha Tripathi,et al.  Resistin in Metabolism, Inflammation and Disease. , 2020, The FEBS journal.

[11]  Stephen Burgess,et al.  PhenoScanner V2: an expanded tool for searching human genotype–phenotype associations , 2019, Bioinform..

[12]  Philip R Jansen,et al.  Obesity, Brain Volume, and White Matter Microstructure at MRI: A Cross-sectional UK Biobank Study. , 2019, Radiology.

[13]  Eden R Martin,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[14]  Zhang Jilin,et al.  Resistin-Inhibited Neural Stem Cell-Derived Astrocyte Differentiation Contributes to Permeability Destruction of the Blood–Brain Barrier , 2019, Neurochemical Research.

[15]  Stephen Burgess,et al.  Genomic atlas of the human plasma proteome , 2018, Nature.

[16]  M. Tomás,et al.  Oxidative stress and the amyloid beta peptide in Alzheimer’s disease , 2017, Redox biology.

[17]  D. Ryglewicz,et al.  Association of adiponectin, leptin and resistin with inflammatory markers and obesity in dementia , 2017, Biogerontology.

[18]  P. Yeung,et al.  Chronic adiponectin deficiency leads to Alzheimer’s disease-like cognitive impairments and pathologies through AMPK inactivation and cerebral insulin resistance in aged mice , 2016, Molecular Neurodegeneration.

[19]  A. Šimundić,et al.  The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia. , 2016, Clinical biochemistry.

[20]  A. Lubkowska,et al.  Serum Adiponectin and Leptin Concentrations in Relation to Body Fat Distribution, Hematological Indices and Lipid Profile in Humans , 2015, International journal of environmental research and public health.

[21]  Y. Shoenfeld,et al.  Obesity in autoimmune diseases: not a passive bystander. , 2014, Autoimmunity reviews.

[22]  S. M. de la Monte,et al.  Brain metabolic dysfunction at the core of Alzheimer's disease. , 2014, Biochemical pharmacology.

[23]  Z. Janka,et al.  Serum adipokine levels modified by donepezil treatment in Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[24]  P. Visscher,et al.  Calculating statistical power in Mendelian randomization studies. , 2013, International journal of epidemiology.

[25]  A. Ferrante,et al.  The immune cells in adipose tissue , 2013, Diabetes, obesity & metabolism.

[26]  Jie Liu,et al.  Resistin protection against endogenous Aβ neuronal cytotoxicity from mitochondrial pathway , 2013, Brain Research.

[27]  K. Chan,et al.  Adiponectin is Protective against Oxidative Stress Induced Cytotoxicity in Amyloid-Beta Neurotoxicity , 2012, PloS one.

[28]  O. Forlenza,et al.  Decreased Levels of Circulating Adiponectin in Mild Cognitive Impairment and Alzheimer’s Disease , 2012, NeuroMolecular Medicine.

[29]  Sudha Seshadri,et al.  Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and alzheimer disease: results from the Framingham Heart Study. , 2012, Archives of neurology.

[30]  Karen L. Mohlke,et al.  Novel Loci for Adiponectin Levels and Their Influence on Type 2 Diabetes and Metabolic Traits: A Multi-Ethnic Meta-Analysis of 45,891 Individuals , 2012, PLoS genetics.

[31]  I. Bondia-Pons,et al.  Oxidative stress and inflammation interactions in human obesity , 2012, Journal of Physiology and Biochemistry.

[32]  G. Sánchez-Rivera,et al.  Inflammation, Oxidative Stress, and Obesity , 2011, International journal of molecular sciences.

[33]  F. Nielsen,et al.  Magnesium, inflammation, and obesity in chronic disease. , 2010, Nutrition reviews.

[34]  E. Ding,et al.  Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. , 2009, JAMA.

[35]  George Davey Smith,et al.  Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology , 2008, Statistics in medicine.

[36]  W. Pan,et al.  Adipokines and the blood-brain barrier , 2007, Peptides.

[37]  S. Yaturu,et al.  Resistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetes. , 2006, Cytokine.

[38]  T. Tai,et al.  Plasma adiponectin levels in overweight and obese Asians. , 2002, Obesity research.

[39]  B. Vellas,et al.  Weight loss in Alzheimer disease. , 2000, The American journal of clinical nutrition.

[40]  M. Castelo‐Branco,et al.  Association between Adipokines and Biomarkers of Alzheimer's Disease: A Cross-Sectional Study. , 2019, Journal of Alzheimer's disease : JAD.

[41]  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019 .

[42]  I. Santana,et al.  The Influence of Adipose Tissue on Brain Development, Cognition, and Risk of Neurodegenerative Disorders. , 2017, Advances in neurobiology.

[43]  F. Villarroya,et al.  Adipokines and the Endocrine Role of Adipose Tissues. , 2016, Handbook of experimental pharmacology.

[44]  M. Weiner,et al.  Lipids and adipokines as risk factors for Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[45]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.